Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘ER+ HER2- breast cancer’

On Hubris and Nemesis

It’s hard to believe we have been following the next generation SERD niche in advanced breast cancer for over five years now, as the trials and tribulations have shaken out along the way.

There were quite a few big Pharma players involved, including some who fell out of the race early such as Novartis and Sanofi, while others such as AstraZeneca have managed to stay the course.

With three major readouts in this space promised this year, including one which already top lined positive, what’s in store for the rest and what can we expect based on what we know so far?

It’s time to gaze into the crystal ball and make some predictions…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

An emerging new target for ER positive breast cancer

River Walk, San Antonio, Texas

The famous colourful umbrellas on the San Antonio river walk always remind me of cute little hats, which is a rather apt metaphor for today’s post on an emerging new target for breast cancer.

We have seen some success in ER+/HER2-negative breast cancers with the aromatase inhibitors and CDK4/6 inhibitors in first-line treatment of the disease and the SERDs elacestrant and fulvestrant in earlier and later lines, respectively, but there is still plenty of room for improvement.

If we want to seek out new targets to address either resistance or even synthetic lethal relationships, how might we go about finding them?

In our latest post on this niche, we discuss an emerging target of interest, highlight the competitors in the early landscape and also offer some commentary from a couple of the companies involved…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

The weird, the wild, and the wonderful

Seeing a Nawlins style paddle boat on a river in Germany is kind of weird, wild, and wonderful all at once!

Following the ESMO Breast Cancer conference in Berlin this weekend, we have some data we’d like to draw your attention to.

These are also key topics for discussion in the broader context of what’s happening in advanced breast cancer and where the field is (or perhaps ought to be) heading next.

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Do ESR1 mutations drive endocrine resistance during the progression of ER+ breast cancer?

Today brings the launch of our series on the AACR annual meeting Previews.  A variety of different topics will be covered over the next two weeks, not just by tumour type and pathway, but also to highlight some novel research that is emerging on various driver mutations that not only can cause resistance to occur, but may also be viable targets for therapeutic intervention.

During the recent Miami Breast Cancer Conference, one Twitter follower who is living with metastatic breast cancer, asked me:

Sadly, the short answer was no.

Many of you will remember, however, that during Dr Debu Tripathy’s detailed of ER+ HER2- positive breast cancer, which I wrote about here, he raised several intriguing points including the possibility that somatic HER2 mutations might be present in some of these patients and thus be a potential therapeutic target. There was no mention of ESR1 though. I spoke to him briefly after his talk and learned that ESR1, while widely known, is really only becoming a hot topic of debate and research now with numerous groups looking into the possibilities.

This led me to research the work of Matt Ellis’s group, as well as what Dana Farber are doing, and also to talk about both HER2 and ESR1 mutations with Dr Vince Miller of Foundation Medicine, whose company is actively doing research in these areas. What he had to say was really compelling and exciting. There is also some new publications as well as interesting data in this area at AACR in San Diego.

To learn more about these sentiments and insights, subscribers can log-in or you can purchase access to BSB Premium Content below… 

This content is restricted to subscribers

error: Content is protected !!